ERBB2 and Thrombocytopenia: Figure 3D demonstrates that none of the six HER2 inhibitor monotherapy users had more than 10% of concurrent thrombocytopenia and bleeding events. However, 40% (44/110) of TDM-1 applicants who experienced hemorrhagic events had coexisting thrombocytopenia (Figure 3E). Thus, TDM-1 had a significantly higher rate of thrombocytopenia with coexisting bleeding events compared to other drugs (p < 0.001) (Figure 3F).